Boston Scientific has launched a docuseries campaign to remove the stigma of male incontinence. Across the videos, the campaign tells the stories of how incontinence upended the lives of three men ...

Analysts said the findings complicate the outlook for a U.S. launch of Boston Scientific's aortic valve replacement device.

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

Investors with a lot of money to spend have taken a bearish stance on Boston Scientific (NYSE:BSX). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third quarter powered by the launch of its Farapulse system for atrial ...

Boston Scientific (BSX) announced it has entered into a definitive agreement to acquire Cortex, Inc., an Ajax Health company. Cortex is a privately held medical technology company focused on the ...

(RTTNews) - Boston Scientific Corporation (BSX) Monday said it has agreed to acquire medical technology company Cortex, Inc. Financial terms of the deal have not been disclosed. Cortex's OptiMap ...

The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.58 per share, indicating an increase of 16% compared to the year-ago period. Analysts forecast ...

Boston Scientific reported Q3 revenue of $4.21 billion, beating estimates. EPS reached $0.63, surpassing consensus of $0.59. Cardiovascular sales rose 25%, and MedSurg increased 10.3% ...

TD Cowen raised the firm’s price target on Boston Scientific (BSX) to $100 from $86 and keeps a Buy rating on the shares. The firm believes they will beat the Street’s 3Q estimates and once ...

On Wednesday, Boston Scientific Corporation (NYSE:BSX) released the results of the primary endpoint of the ACURATE IDE trial of ACURATE neo2 Aortic Valve System for patients with severe ...

On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter revenues of $4.21 billion, beating the consensus estimate of $4.04 billion. Sales increased 19.4% on a reported basis ...